C. M. Kruijtzer

Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview.

J. Schellens, J. Beijnen, C. M. Kruijtzer, 2002, The oncologist.

Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands

J. Verweij, J. Beijnen, W. W. ten Bokkel Huinink, 2000, Anti-Cancer Drugs.

Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.

J. Schellens, H. Rosing, J. Beijnen, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer.

J. Schellens, H. Rosing, J. Beijnen, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer

J. Beijnen, J. Schornagel, W. W. ten Bokkel Huinink, 2006, British Journal of Cancer.

Successful treatment with paclitaxel of a patient with metastatic extra-adrenal pheochromocytoma (paraganglioma)

J. Schellens, J. Beijnen, M. Swart, 2000, Cancer Chemotherapy and Pharmacology.

Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer.

H. Rosing, J. Beijnen, J. Schellens, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer

J. Schornagel, M. Schot, H. Helgason, 2006, British Journal of Cancer.